| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/22/2004 | EP1459742A2 Agent for prophylaxis and treatment of asthenopia and pseudomyopia |
| 09/22/2004 | EP1459741A1 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with menthylphenidate |
| 09/22/2004 | EP1459739A1 Non-hygroscopic pharmaceutical compositions containing non-hydrated quinoline carboxylic acids |
| 09/22/2004 | EP1459737A1 Granules containing acid-unstable chemical in large amount |
| 09/22/2004 | EP1458888A2 Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene |
| 09/22/2004 | EP1458870A1 COMPOSITIONS AND PROCESSES USING siRNA, AMPHIPATHIC COMPOUNDS AND POLYCATIONS |
| 09/22/2004 | EP1458865A2 Human vanilloid receptor protein and polynucleotide sequence encoding same |
| 09/22/2004 | EP1458864A1 Tgf-beta-specific covalently closed antisense molecule |
| 09/22/2004 | EP1458863A1 A system for stable expression of sirnas in mammalian cells |
| 09/22/2004 | EP1458754A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control |
| 09/22/2004 | EP1458747A1 Template-fixed peptidomimetics as inhibitors of serine proteases |
| 09/22/2004 | EP1458745A2 SUBSTITUTED AMINO CARBOXAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| 09/22/2004 | EP1458743A1 Tetrahydrobenzfluorene derivatives |
| 09/22/2004 | EP1458741A2 Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| 09/22/2004 | EP1458737A2 Biosynthetic gene cluster for the maytansinoid antitumor agent ansamitocin |
| 09/22/2004 | EP1458735A2 Anti-viral 7-deaza l-nucleosides |
| 09/22/2004 | EP1458734A1 Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
| 09/22/2004 | EP1458733A1 Silver salts of sucrose-octasulphate |
| 09/22/2004 | EP1458732A1 Method for preparing a glucosamine compound, and compound thus obtained |
| 09/22/2004 | EP1458728A1 Crystalline cefdinir potassium dihydrate |
| 09/22/2004 | EP1458726A2 Mitotic kinesin inhibitors |
| 09/22/2004 | EP1458725A1 A novel sordarin derivative isolated from culture fermentations and functions as an antifungal agent |
| 09/22/2004 | EP1458723A1 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function |
| 09/22/2004 | EP1458722A1 Pyrrolopyrimidines as phosphodiesterase vii inhibitors |
| 09/22/2004 | EP1458721A1 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino 4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use |
| 09/22/2004 | EP1458720A1 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
| 09/22/2004 | EP1458719A1 Pyridoquinoxaline antivirals |
| 09/22/2004 | EP1458718A1 Quinolinones as prostaglandin receptor ligands |
| 09/22/2004 | EP1458717A1 Aroyl pyridinones |
| 09/22/2004 | EP1458716A1 Bicyclic n-arylamides |
| 09/22/2004 | EP1458715A1 Novel compounds |
| 09/22/2004 | EP1458714A1 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives |
| 09/22/2004 | EP1458713A1 Indolinone derivatives useful as protein kinase inhibitors |
| 09/22/2004 | EP1458712A2 Novel compounds |
| 09/22/2004 | EP1458711A1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer s disease and conditions associated with glycogen synthase kinase-3 |
| 09/22/2004 | EP1458710A1 Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| 09/22/2004 | EP1458709A1 New process |
| 09/22/2004 | EP1458708A2 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| 09/22/2004 | EP1458707A2 New compounds |
| 09/22/2004 | EP1458706A1 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 09/22/2004 | EP1458704A1 Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors |
| 09/22/2004 | EP1458703A1 Isochroman compounds for treatment of cns disorders |
| 09/22/2004 | EP1458702A1 Luminacin analogs and uses thereof |
| 09/22/2004 | EP1458697A1 Biphenylmethyl-thiazolidinediones and analogues and their use as ppar-gamma activators |
| 09/22/2004 | EP1458694A2 Therapeutic compounds for treating dyslipidemic conditions |
| 09/22/2004 | EP1458693A1 Amorphous and crystalline forms of losartan potassium and process for their preparation |
| 09/22/2004 | EP1458690A1 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
| 09/22/2004 | EP1458689A1 Aryloxyphenyl and arylsulfanylphenyl derivatives |
| 09/22/2004 | EP1458688A1 Quinazolinone derivative |
| 09/22/2004 | EP1458687A2 Pyrimidine compounds |
| 09/22/2004 | EP1458686A1 Benzocyclodecane derivatives with antitumor activity |
| 09/22/2004 | EP1458684A2 Therapeutic heterocycles |
| 09/22/2004 | EP1458683A1 Heteroaryl-substituted aminocyclohexane derivatives |
| 09/22/2004 | EP1458682A1 1,4-dihydro-1,4-diphenylpyridine derivatives |
| 09/22/2004 | EP1458681A1 Hydrophilic (s)-amlodipine salts or their hydrates and pharmaceutical compositions |
| 09/22/2004 | EP1458680A1 Prodrugs to d-prolines |
| 09/22/2004 | EP1458679A2 Pyrrolidine derivatives as prostaglandin modulators |
| 09/22/2004 | EP1458677A1 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha |
| 09/22/2004 | EP1458676A2 Compounds for the treatment of inflammatory disorders |
| 09/22/2004 | EP1458673A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) |
| 09/22/2004 | EP1458672A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha(ppar) |
| 09/22/2004 | EP1458671A1 Prodrugs of excitatory amino acids |
| 09/22/2004 | EP1458447A2 Combination of cytochome p 450 dependent protease inhibitors |
| 09/22/2004 | EP1458429A1 Resorbable polymer composition, implant and method of making implant |
| 09/22/2004 | EP1458427A2 Compositions comprising collagen and metalloprotease inhibitors |
| 09/22/2004 | EP1458421A1 Composition for treating contact lenses in the eye |
| 09/22/2004 | EP1458418A1 Disinfection agent for suction systems used in the field of medicine |
| 09/22/2004 | EP1458413A2 Pharmaceutical compositions based on azetidine derivatives |
| 09/22/2004 | EP1458412A1 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 09/22/2004 | EP1458405A1 Use of fk506 and analogues for treating allergic diseases |
| 09/22/2004 | EP1458404A1 Polyphenol inhibition of nucleoside diphosphate kinase-b activity and cancer metastasis |
| 09/22/2004 | EP1458402A1 Improvements in or relating to liquid, eye-instillable preparations comprising sodium hyaluronate |
| 09/22/2004 | EP1458401A1 Composition comprising dextrinsulfate for the treatment of sexual transmitted diseases (std) |
| 09/22/2004 | EP1458400A1 Liquid bisphosphonate formulations for bone disorders |
| 09/22/2004 | EP1458399A1 Pregnane steroids for use in the treatment of cns disorders |
| 09/22/2004 | EP1458398A1 Antibiotic formulation and a method of making this formulation |
| 09/22/2004 | EP1458397A1 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
| 09/22/2004 | EP1458395A1 New use |
| 09/22/2004 | EP1458394A1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer s disease and conditions associated with glycogen synthase kinase-3 |
| 09/22/2004 | EP1458393A1 Substituted diketopiperazines as oxytocin antagonists |
| 09/22/2004 | EP1458392A2 Acridone inhibitors of impdh enzyme |
| 09/22/2004 | EP1458391A1 A method of treating bacterial infections using gemifloxacin or a salt thereof and a beta-lactam antibiotic |
| 09/22/2004 | EP1458390A1 A method of treating bacterial infections using gemifloxacin or a salt thereof and a carbapenem antibacterial agent |
| 09/22/2004 | EP1458389A1 Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion |
| 09/22/2004 | EP1458388A1 A liquid pharmaceutical formulation comprising nicotine for the administration to the oral cavity |
| 09/22/2004 | EP1458387A2 Orodispersible tablets containing fexofenadine |
| 09/22/2004 | EP1458386A1 Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
| 09/22/2004 | EP1458385A2 Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
| 09/22/2004 | EP1458384A1 Amlopidine bezylate tablets with improved stability |
| 09/22/2004 | EP1458383A2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| 09/22/2004 | EP1458382A1 Amide derivatives as gk activators |
| 09/22/2004 | EP1458381A1 Triazoles as oxytocin antagonists |
| 09/22/2004 | EP1458380A1 Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors |
| 09/22/2004 | EP1458379A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 09/22/2004 | EP1458378A1 Amino acid derivatives useful for the treatment of alzheimer's disease |
| 09/22/2004 | EP1458377A1 5ht4 partial agonist pharmaceutical compositions |
| 09/22/2004 | EP1458376A1 Darifenacin for use in the treatment of urgency induced by overactive bladder |
| 09/22/2004 | EP1458375A2 Compositions for decreasing activity of hormone-sensitive lipase |
| 09/22/2004 | EP1458374A2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 09/22/2004 | EP1458373A1 Use of lipoxin analogs to promote cell defense against gram-negative infections |